ARTICLE | Company News

Ex-Onyx CEO Coles, MIT's Lindquist launch Yumanity

December 16, 2014 3:17 AM UTC

Former Onyx Pharmaceuticals Inc. CEO Tony Coles and Massachusetts Institute of Technology Professor Susan Lindquist have teamed up to launch Yumanity Therapeutics LLC (Cambridge, Mass.), a newco targeting protein misfolding diseases. Yumanity will focus initially on neurodegenerative disorders including Alzheimer's disease (AD), Parkinson's disease (PD) and amyotrophic lateral sclerosis (ALS).

The company's three-part approach to drug development involves an ultra-high throughput phenotypic screening (uHTS) platform, a drug-target identification platform and stem cell-derived neurons from patients with disease-causing genetic mutations. The discovery platforms were developed in Lindquist's lab at the Whitehead Institute and the Howard Hughes Medical Institute. ...